Pyrilutamide

Pyrilutamide

Clinical data
Other names	KX-826; KX826
Routes of administration	Topical [1]
Drug class	Nonsteroidal antiandrogen; Androgen receptor antagonist
ATC code	None
Identifiers
IUPAC name 4-(3-(4-cyano-2-fluoro-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide
CAS Number	1272719-00-2
PubChem CID	50940514
ChemSpider	115037042
Chemical and physical data
Formula	C21H15F5N4O2S
Molar mass	482.43 g·mol−1
3D model (JSmol)	Interactive image
SMILES CNC(=O)C1=C(F)C=C(C=C1)N1C(=S)N(C(=O)C1(C)C)C1=C(F)C(=C(C=C1)C#N)C(F)(F)F
InChI InChI=1S/C21H15F5N4O2S/c1-20(2)18(32)29(14-7-4-10(9-27)15(16(14)23)21(24,25)26)19(33)30(20)11-5-6-12(13(22)8-11)17(31)28-3/h4-8H,1-3H3,(H,28,31) Key:CGRMNGGGSWLDDC-UHFFFAOYSA-N

Pyrilutamide (developmental code name KX-826) is a nonsteroidal antiandrogen (NSAA) which is under development for the treatment of androgenic alopecia (pattern hair loss) and acne. ^{[1] [2] [3]} The drug is being developed by Suzhou Kintor Pharmaceuticals. ^[1] As of February 2025, it is in phase 3 clinical trials for androgenic alopecia and phase 2 trials for acne. ^[1] The drug was also under development for the treatment of diabetic foot ulcers, but development for this indication was discontinued. ^[1]

Pharmacology

Pharmacodynamics

Pyrilutamide is a selective and high-affinity silent antagonist of the androgen receptor (AR). It has an affinity (IC₅₀ Tooltip half-maximal inhibitory concentration) of 0.28 nM, relative to 3.1 nM in the case of bicalutamide. ^[3]

See also

• List of investigational acne drugs
• List of investigational hair loss drugs
• GT-20029 (AR-PROTAC)
• Clascoterone (Winlevi; Breezula; CB-03-01)

References

1. "Pyrilutamide - Suzhou Kintor Pharmaceuticals". AdisInsight. Springer Nature Switzerland AG.
2. Saceda-Corralo D, Domínguez-Santas M, Vañó-Galván S, Grimalt R (January 2023). "What's New in Therapy for Male Androgenetic Alopecia?". American Journal of Clinical Dermatology. 24 (1): 15–24. doi:10.1007/s40257-022-00730-y. PMID   36169916.
3. CApatent 2829322,Tong Y,"Substituted Thioimidazolidinone Androgen Receptor Antagonists and Uses Thereof",published 2012-03-08,issued 2017-01-10, assigned to Suzhou Kintor Pharmaceuticals, Inc